Marker for therapy response in AML identified
With the combination of the drugs Venetoclax and 5-Azacitidine, a new, effective and more tolerable…
Browsing: Featured
Antibody fragment-nanoparticle therapeutic eradicates cancer
A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer…
How genome doubling helps cancer develop
A single cell contains 2-3 meters of DNA, meaning that the only way to store…
What is Adaptive Therapy? ANZadapt Trial with Craig Gedye
What is adaptive therapy? How has evolutionary game theory inspired a new approach to prostate…
CAR T cell robots based on magnetic-acoustic actuation developed for precise antitumour immunotherapy
Although chimeric antigen receptor (CAR) T cell therapy has shown potential in the treatment of…
Somatic genome editing therapies are becoming a reality – but debate over ethics, equitable access and governance continue
Olga C. Pandos, University of Adelaide Hundreds of experts from around the world gathered at…
New paper introduces ethics framework for use of Generative AI in healthcare
A new paper published today by leading Australian AI ethicist Stefan Harrer PhD proposes for…
Long-term exposure to nitrate in drinking water may be a risk factor for prostate cancer
The nitrate ingested over the course of a person’s adult lifetime through the consumption of tap…
Algorithm offers new way to spot patients likely to respond to immunotherapy
Scientists have developed a new way of using cancers’ DNA to spot cancer patients who…
EAU 2023: Delaying treatment for localised prostate cancer does not increase mortality risk
Active monitoring of prostate cancer has the same high survival rates after 15 years as…